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ABSTRACT 
 
Glioblastoma is the most aggressive primary tumor of the central nervous system with 
a medium overall survival of 7-15 months after diagnosis. Since tumor cells penetrate the 
surrounding brain tissue, complete surgical resection is impossible and tumor recurrence is 
almost a certainty. New treatment modalities are therefore needed, and these should be able 
to trace, identify, and kill dispersed tumor cells with great accuracy. Immunological 
approaches in principle meet these needs. Unfortunately, due to profound tumor-associated 
mechanisms of immunosuppression and -evasion, immunotherapeutic strategies like peptide 
vaccination have so far not been translated into clinical success. If future, peptide-based 
vaccination approaches shall be successful in glioblastoma therapy, multiple questions need 
to be solved including identification of suitable antigens, route and mode of vaccination, 
preparation of the tumor-bearing “host” and antagonizing, as much as this is possible, 
glioblastoma-associated mechanisms of immune evasion and poor vaccination response. In 
this review we will address the immunological challenges of glioblastoma and discuss key 
aspects that have rendered successful immunotherapy difficult in the past.  
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INTRODUCTION 
 
 Glioblastoma is the most common primary malignancy of the central nervous system 
and represents almost 50% of all primary intracranial neoplasias.1 Because of the early 
infiltration of surrounding tissue, the high recurrence rate with fast progression, and the 
inability to completely eliminate the tumor glioblastoma evades successful treatment so far. 
Despite substantial advances and treatment refinements during the last decades, 
conventional therapies like neurosurgical resection and multimodal radio- and chemotherapy 
have limited effects on disease progression, recurrence rate or clinical outcome. 
Consequently, patients with newly diagnosed glioblastoma experience a median overall 
survival of only 7-15 months.2,3 Despite extensive research, the prognosis for these patients 
has only improved by 3-6 months over the past decades.4 
 
 Although the clinical outcome is influenced by individual factors like MGMT-promoter-
methylation,5 isocitrate dehydrogenase (IDH) mutations, age and Karnofsky performance 
score (KPS) at initial diagnosis,6 as well as the location, configuration and surgical 
accessibility of the tumor, the dominating pathological feature of glioblastoma remains its 
high recurrence rate. While metastases to other organs are rare, and less than 10% of 
malignant gliomas reoccur distant to the original site, local recurrence is almost certain.7 A 
major factor responsible for the high recurrence rate is the ability of malignant cells to 
migrate and penetrate deeply into the surrounding parenchyma. Using white matter fiber 
tracts as well as feeding blood vessels as guiding pathways, tumor cells can spread and 
infiltrate anatomical structures adjacent to the primary tumor, so that dispersed tumor cells 
can be found centimeters away.8,9 Since the brain does not allow expanded surgical en-bloc 
resection, neurosurgical treatment is restricted to reducing tumor burden. Therefore, while 
neurosurgical intervention remains one of the most important treatment approaches and the 
introduction of microscope-guided surgery improved the extent of surgical resection, 
complete surgical tumor removal remains impossible.10  
 
Other treatment modalities such as radio- or chemotherapy using alkylating agents 
like temozolomide have increased the overall life expectancy, but their effects are limited. 
One reason for the intractability of glioblastoma is the transforming nature and dynamic 
molecular phenotype of glioblastoma, which includes multiple mechanisms to resist drug- 
and radiation-induced anti-tumor activity.11,12 In addition, malignant gliomas are characterized 
by their heterogeneity, which is promoted by tumor-initiating cells that drive a constantly 
mutating cancer cell population.13 The transforming nature of a heterogeneous tumor further 
facilitates the generation of defense mechanisms against radio- and chemotherapy. Although 
both treatment modalities prolong overall survival, they lack specificity and are accompanied 
by substantial side effects. New effective and more specific treatment modalities are 
therefore urgently needed. 
 
Key Players in Immunotherapy 
 
The immune system is not only engaged in defending the body from foreign 
pathogens, but it is also involved in eliminating cells that underwent malignant transformation 
in a process called “immune surveillance”.14 Processes of malignant transformation are 
driven by genetic instability including changes in genes that are involved in cell cycle control, 
migration, angiogenesis, apoptosis, and also mutations of genes encoding for “normal” 
proteins not directly involved in tumor biology.15 The immune system is able to recognize 
transformed cells and in analogy to vaccinations for infections, immune responses against 
tumor tissue can in principle be enhanced in an active or a passive fashion.16 In contrast to 
prophylactic vaccinations against infections, cancer immunotherapy aims at eradicating 
established diseases, i.e. is analogous to therapeutic vaccination. 
 
The basic principle of cancer immunotherapeutic approaches is to evoke a tumor-
specific cellular immune response resulting in the selective elimination of cancer cells. The 
central effector population for targeted cancer cell lysis is comprised of CD8+ T cells, also 
called cytotoxic T lymphocytes (CTL).17 CD8+ T cells can identify antigenic peptides, which 
are presented by human leukocyte antigen (HLA) class I molecules on the surface of cancer 
cells with their antigen-specific T cell receptor (TCR).18 The interaction of the TCR with the 
presented tumor antigen, together with costimulatory molecules like B7-1/2 will result in the 
targeted release of CTL effector molecules like perforin and granzyme, which induce 
apoptosis, as well as cytokines such as interferon-γ (IFN-γ) and tumor necrosis factor-α/β 
(TNF-α/β). The potent CTL response is supported by a complex interaction of other immune 
cells, responsible for priming and amplification of the anti-tumor effect. An important part of 
the priming/activating immune cells are professional antigen-presenting cells (APCs), mainly 
represented by dendritic cells (DCs) which can take up tumor-associated proteins and/or 
peptides and, after intracellular processing, present them via HLA class I and -II molecules 
on their surface.19 Although there is some cross-talk between these two processing and 
presentation pathways, presentation via HLA class I will mainly prime CD8+ CTL, while 
peptide binding to HLA class II will induce a CD4+ Thelper cell response.20 Type 1 helper cells 
specific for tumor antigens are able to amplify CTL proliferation and enhance their anti-tumor 
effect. By creating a local proinflammatory environment, for example, by secreting cytokines 
like IL-2 or IFN-γ among others Thelper cells promote the local reactivation of CTL by APC. 
This means, in order to mount an efficient tumor-specific immune response, both CTL as well 
as Thelper cell activation against tumor antigens that are presented in the context of HLA-class 
I and -class respectively are required (Figure 1).  
 
As we would like to focus on immunological challenges that are relevant to improve 
immunotherapeutic protocols in a clinical setting, we will not introduce all molecules and cell 
populations, for example NK- and NK-T-cells, that are additionally involved in the complex 
interaction between immune- and cancer cells, but focus on the adaptive T cell-mediated and 
tumor specific immune responses.   
 
Peptide-based immunotherapeutic approaches 
 
Tumor vaccination protocols can either be based on vaccination with a peptide or 
protein, ideally one that is specific and relevant for the respective tumor. Different protocols 
using tumor-specific peptide antigens have been established. Crude peptide digests of the 
autologous tumor can be used for vaccination, but in most cases synthetically manufactured 
peptides are injected subcutaneously or intranodally to prime the host immune system and to 
expand existing tumor-specific CTL.21 Theoretically, if the immune response is strong enough 
and sufficient numbers of tumor-specific CD8+ T cells expand, cell-mediated lysis of the 
tumor cells could lead to tumor regression,22 and a cure is at least a possibility. Another 
immunotherapeutic approach is the adoptive transfer of autologous or genetically engineered 
tumor-specific T cell populations. Although adoptive T cell transfer harbors great potential, 
we will focus here on the more clinically feasible peptide-based immunotherapeutic 
approaches.  
 
Another approach of inducing a tumor-specific immune reaction is dendritic cell 
vaccination. Ralph Steinman`s discovery of DCs and their potent antigen presenting function 
provided the rationale for DC vaccination protocols. Compared to peptide vaccination, 
vaccination with peptide-pulsed DCs is considerably more labor-intensive, requires a GMP 
laboratory, and therefore poses both technical and financial hurdles. It involves the isolation 
of large numbers of peripheral blood mononuclear cells (PBMCs) from the patient using 
leukapheresis. Out of the heterogeneous cell mixture of PBMCs, CD34+ or monocytic cells 
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substitutionfter exposure to whole tumor cells, tumor cell lysates, tumor RNA or specifically 
selected peptide mixtures, the pulsed dendritic cells are readministered to the patient. Due to 
the excellent antigen presentation and density of costimulatory molecules, mature DCs in 
consequence are able to effectively stimulate the expansion of tumor-specific T cells.23 As for 
peptide vaccination, the selection of the appropriate antigen for the loading of DCs is of 
major importance. Approaches that use unspecific tumor extracts carry the risk of severe 
autoimmune collateral damage.24 
 
Limits of current immunotherapeutic approaches 
 
A substantial number of clinical vaccination trials for malignant gliomas have been 
conducted. While tumor immunotherapeutic approaches in animals have led to significant 
tumor reduction and produced long-term tumor immunity, anti-tumor efficacy in human trials 
has so far been disappointing throughout all cancer entities including glioblastoma. Despite 
many phase I- and an increasing number of phase II trials, only one peptide vaccine for 
hormone-refractory prostate cancer was approved by the FDA.25 A metaanalysis by 
Rosenberg et al. summarized the poor results of peptide vaccination trials that were 
performed until 2006. Using objective criteria of tumor response, of 440 patients only 12 
(2.6%) responded to vaccination treatment.26  
 
 The in vivo response rate has been particularly low in high-grade gliomas and 
resistance towards an immune-mediated tumor regression is a hallmark of glioblastoma.27 It 
appears that not only the initiation, but also the execution of tumor-directed effector functions 
poses considerable obstacles in the treatment of glioblastoma. To achieve clinical success, 
several factors like efficient T cell activation, selection of the best antigens and peptides, 
immunogenic presentation as well as ways to overcome glioblastoma-associated immune 
evasion mechanisms or immunosuppression, have to be considered. Considering the 
sobering results of clinical trials, but also the at least theoretically promising advances in 
tumor immunology we decided to review and critically discuss immunological aspects of 
vaccination strategies to treat glioblastoma. 
 
Promising data from clinical studies 
 
It has been shown for other malignancies that peptide-based immunotherapy is able 
to mount a safe and effective immune response. In a randomized phase 3 trial enrolling 185 
patients with advanced melanoma, the vaccine, consisting of the HLA*A02:01-restricted 
peptide gp100:209-217(210M) plus incomplete Freund`s adjuvant, was administered 
followed by interleukin-2 and compared to interleukin-2 alone. The vaccine group had a 
significantly higher response rate, as well as longer progression-free survival than the control 
group, which received the cytokine alone.28 A therapeutic vaccine for HLA-A*02+ renal cell 
cancer patients consisting of multiple tumor-associated peptides was safe and already 
showed improved disease control in a phase 1 trial.  Immunomodulation using single-dose 
cyclophosphamide with the aim of purging regulatory T cells that prevent efficient tumor-
specific immune activation has been linked to prolonged survival among those patients, who 
mounted a specific immune response to the vaccine.29 
 
As the first trial advancing to phase III testing, peptide-vaccination targeting the 
epidermal growth factor receptor (EGFR) mutation III (vIII) is currently one of the most 
prominent examples for immunotherapy for glioblastoma.30,31 The preceding EGFRvIII trial 
results can offer important insights into in vivo dynamics of a peptide vaccine, which we 
would like to discuss briefly from an immunological perspective. In general, the EGFR is a 
tyrosine kinase overexpressed in up to 50% of tumors.32 The EGFRvIII is a mutated form of 
this receptor, harboring a constant deletion within the extracellular domain. The peptide used 
in the EGFRvIII trials spans this mutated EGFR region, thereby displaying a tumor-specific 
neoantigen for T cell-mediated immunotherapy that is not expressed in normal tissue. 
Although this mutation is present in up to 20% of high-grade gliomas, the high tumor 
heterogeneity results in a large proportion of cells (24-63%), which do not express this 
antigen.30,33  
 
 A phase II trial, named ACTIVATE, applied the classical peptide vaccination protocol. 
The treatment regimen consisted of surgical tumor resection (gross total resection > 95%) 
followed by radiotherapy combined with temozolomide treatment. After completion of 
chemotherapy the patients had to be progression free for 4 weeks before being vaccinated 
with the peptide. The 14-amino-acid long, EGFRvIII peptide was administered 
subcutaneously every two weeks together with an immune booster (GM-CSF). Patients were 
monitored every two months with MRI. If radiographic progression was detected, therapy 
was discontinued. Results demonstrated prolonged progression free survival and mean 
overall survival of vaccinated patients compared to a historically matched cohort.34,35 Clinical 
efficacy of the EGFRvIII peptide vaccination will be further assessed in an international multi-
center randomized double blind placebo controlled trial called ACT IV. 
 
 So far, the EGFRvIII trials generated two immunologically interesting results relevant 
for future glioma vaccinations. First, patients, in whom an EGFRvIII-specific antibody 
response was detected, had a significantly prolonged overall survival raising the interesting 
point that not only T cell-mediated, but also humoral, i.e. antibody-mediated, tumor-specific 
immune responses can be mounted. This implies a correlation of successful induction of 
immunity and the consequent translation into clinical success. Second, 82% of all recurring 
tumors demonstrated loss of the EGFRvIII mutation,35 indicating a successful induction of an 
immune-mediated tumor cell lysis, however, at the same time evasion of the tumor. The 
turnover, high prevalence of mutations and the great heterogeneity of glioblastoma seem to 
easily overcome vaccination with a single antigen. Although, the selection of EGFRvIII 
negative tumor cells can possibly promote a more indolent tumor expansion, a plethora of 
growth-enhancing mutations ensures continuous cell growth, which then also might lead to 
an exceedingly aggressive phenotype. 
 
With a great variety of clinical trials using immunotherapy for cancer, additional interesting 
data can be expected in the near future. Table 1 summarizes ten ongoing clinical trials using 
peptide-based vaccination to apply immunotherapy to glioblastoma.  
 
IMMUNOLOGICAL CHALLENGES OF GLIOBLASTOMA  
 
 Immunotherapy can be successful because not only in vitro but also in vivo studies 
have shown that it is possible to induce a tumor-specific immune response. Glioblastoma 
patients exhibit significant in vivo frequencies of tumor-specific T cells without prior 
stimulation via a vaccinating agent.36 Experiments using murine models demonstrated that 
long-term immunity and effective tumor rejection can be stimulated by vaccination.37 
Additional data dissecting human glioblastoma tissue phenotypes further discovered a 
correlation between the magnitude of CD8+ T cell infiltration and a prolonged overall 
survival.38,39 Such data provides evidence of the immune system`s ability to limit tumor 
progression. Unfortunately, until today clinical trials have not been able to translate these 
findings into clinical success. Since increasing evidence suggests the presence of a complex 
tumor-host interaction, we will review the immunological aspects of glioblastoma 
pathophysiology in the following sections.  
 
Tumor evasion and immunosuppression 
 
 Malignant tumors are often depicted as a homogeneous cell population, which is 
characterized by uncontrolled cell growth. This view has changed over the past decades.40 
Tumors, and especially malignant gliomas, have been shown to interfere not only with the 
surrounding tissue, e.g. activating angiogenesis, but also to interact with the immune 
system.27 Although the brain is conventionally considered an immunoprivileged organ, 
immune cells constantly cross the blood brain barrier, albeit to a lesser extent compared to 
other organs like skin or gut. Since the immune system is able to identify malignant cells in 
the early stages of tumor formation in a process called cancer immunosurveillance,14 initial 
mutations in the cancerogenesis of glioblastoma most likely confer characteristics that help 
to evade or suppress the immune system or, alternatively, are not “seen” by immune cells in 
a sufficiently immunogenic context to mount an efficient tumor response. This indicates that 
the immune system may present as a selection-factor in tumor development, also described 
by the term immunoediting in analogy to immune receptor editing.41 Tumor evasion is 
generally thought to be due to low expression of immunogenic target antigens by tumor cells, 
rendering them “poorly visible” for T cells, while immunosuppression is defined by multiple 
mechanisms that inhibit adaptive anti-tumor immune responses.27,42 Only malignant cells that 
have gained the ability to suppress and/or evade the immune system survive and evolve to a 
progressing malignancy. Further, driven by cancer stem- or glioma-initiating cells (GSC) the 
tumor continuously de-differentiates, differentiates and renews itself, with the result of 
compromising the immune system`s ability to identify and distinguish malignant from normal 
brain tissue.13  
 
Studies investigating glioblastoma tissue composition revealed that up to 3.2% of 
cells within a tumor express the pan T cell marker CD3, demonstrating the local presence of 
immune effector cells.43 Although a remarkable amount of tumor-infiltrating lymphocytes (TIL) 
seems to be tumor-antigen specific, most of them do not execute any effector functions or 
contribute to tumor regression - they virtually have been rendered silent.44-46 Especially, high-
grade gliomas have been shown to suppress, modulate and evade the immune system at 
multiple levels.27,41 Hereby the tumor not only alters its immunological appearance, but also 
plays an active role by manipulating the immune system in its favor. 
 
In the local tumor environment, soluble factors like prostaglandine E2 (PGE2), 
transforming growth factor beta (TGF-) and interleukin-10 (IL-10) have been described to 
affect immune function.44,47,48 PGE2 inhibits T cell activation, suppresses NK cell activity, 
downregulates HLA class II expression and induces upregulation of FoxP3 and production of 
IL-10 in non-Treg cells, steering immune cell composition towards a Treg phenotype.49-51 TGF- 
inhibits T cell proliferation, activation and the function of cytotoxic molecules like perforin or 
granzymes.51 In addition, TGF- impedes DC maturation and antigen presentation, working 
synergistically with IL-10 in preventing T cell activation and IL-2-induced proliferation.52,53 
TGF- is partly controlled by adhesion molecule signaling. Integrins like αv, β3 or β5 have 
been found to control the TGF- pathway in glioblastoma.47 Moreover, these soluble factors 
can be produced by the glioma cells themselves or by local immune cells.27  
 
As mentioned above, immune cell infiltration represents a strong feature of gliomas. 
Almost 25% of all tumor-infiltrating lymphocytes express the regulatory T cell markers CD4, 
CD25 and FoxP3.54 Interestingly, the infiltration of CD4+ CD25+ regulatory T cells correlates 
with glioma malignancy grade,55 suggesting that malignant progression is closely associated 
with increased attraction of regulatory T cells. The increased recruitment directly correlates 
with a negative impact on survival.42 The suppression of anti-tumor immune responses, 
however, is not only restricted to the local tumor environment but also appears to extend to a 
systemic level, since tumor-specific regulatory T cells were also found to be elevated in 
peripheral blood of glioma patients.56,57 As a consequence an impaired CD4+ T cell 
proliferation was observed due to the increased fraction of Tregs in glioblastoma.58,59  
 
Along with active immunosuppression, glioblastoma mechanisms evolved to evade 
and counteract CTL-mediated lysis. As mentioned above, a tumor-specific T cell can only 
identify the tumor if it recognizes tumor antigen bound to surface HLA class I. Mutations 
within the peptide processing machinery such as altered peptide cleavage or loss of TAP 
expression, have been described.60 Further, complete loss of genomic DNA encoding for 
certain HLA alleles, HLA gene hypermethylation or alterations in chromatin structure of HLA 
promoter regions have been demonstrated in glioblastoma.61 Most efficient for cancer cells is 
the selective loss of 2-microglobulin, which abrogates expression of all HLA class I 
molecules.62 As a result, 22-43% of tumor cells within a tumor do not express HLA class I, 
rendering the cancer cells invisible to CTLs.61,63  
 
One mechanism of the immune system to counteract tumor-associated loss of HLA 
class I expression is NK cell-mediated lysis.64 NK cells expressing the killer immunoglobulin-
like receptor (KIR) are activated if the HLA class I molecule is absent.65 Recently, HLA-G has 
been described to bind to the inhibitory ILT2 receptor expressed by NK cells, thereby 
counteracting NK cell activation and CTL-based tumor lysis. HLA-G is expressed by several 
tumors including glioblastoma, which may contribute to protection from NK cell killing after 
loss of HLA class I.66 In addition, malignant gliomas have been shown to also express HLA-
E, another non-classical HLA-molecule that inhibits NKG2D-mediated tumor cell lysis.67-70 
 
An additional mechanism to hinder immune- and cancer cell interaction is the 
impairment of adhesion molecule functions. For example, expression of the intercellular 
adhesion molecule (ICAM-1, CD54) is required for tumor rejection in vivo.71 Since target cell 
lysis and T cell recognition of TAA presented by HLA class I is dependent on LFA-1/ICAM-1 
interaction, the disruption of this mechanism leads to impaired T cell activation.72,73 Further, 
extracts from U251 glioma cell lines have shown that extracellular matrix proteins like 
tenascin-C can inhibit T cell proliferation and cytokine production.74,75 Glioma cells can also 
secret glycosaminoglycans, consequently creating a mechanical barrier for immune cell 
infiltration.76 
 
Among other described immunosuppressive pathways like the Fas/FasL- or Galectin-
1-interaction,77,78 we would like to highlight two interesting molecules, which are under 
current investigation – signal transducer and activator of transcription 3 (STAT3) and 
indolamine 2,3-dioxygenase (IDO). STAT3 signaling positively regulates production of anti-
inflammatory cytokines and anti-apoptotic factors. The observed constitutive overexpression 
in glioma cells results in the upregulation of anti-apoptotic factors, supposedly conferring an 
enhanced resistance to chemo-, radio- and CTL-based immunotherapy.79 Interestingly, in 
contrast to normal human astrocytes, the silencing of STAT3 expression in glioma cells 
mediated their apoptosis in the absence of an apoptotic stimulus. Glioma cells can also 
express IDO, which is an inducible enzyme expressed under the influence of a variety of 
cytokines, including IFN-γ or TGF-β. IDO catalyzes the degradation of the amino acid 
tryptophan, which is essential for T cell proliferation.80 The tryptophan-deprived local tumor 
environment can lead to T cell anergy and apoptosis, thereby impairing T cell activation in 
the local tumor environment.81,82 
 
Together, the immunomodulatory mechanisms reviewed above primarily impair T cell 
activation, cytokine production and execution of effector functions. As a result, the local 
tumor environment counteracts an effective anti-tumor response. All peptide vaccination 
strategies will face the challenge of overcoming the local immunosuppression. Although well 
designed vaccination protocols will presumably be able to recruit large quantities of tumor-
specific immune cells, a combined approach that simultaneously tackles the 
immunosuppressive mechanisms of glioblastoma will most likely be inevitable.  
 
Challenges in antigen selection 
 
Tumor-specific CTLs need to directly interact with the glioma cell to execute their 
tumor lysing effector functions. This cell-cell-interaction, also called immunological synapse, 
is mainly defined by the tumor-specific TCR and its cognate tumor-antigen:HLA complex, as 
well as costimulatory molecules.83 When searching for the ideal tumor antigen for peptide 
vaccination, the following considerations have to be taken into account: 1) CTLs can only 
induce apoptosis and lyse tumor cells, if their specific antigen is naturally presented on a 
HLA class I molecule. 2) HLA class I molecules are highly polymorphic – different allelic 
variants bind different sets of peptides.84 3) To avoid autoimmunity, the ideal antigen should 
be expressed exclusively on tumor tissue, or, if an autoimmune response against an antigen 
should develop, the respective target organ/cell should not lead to major toxicity.  
 
The HLA molecules, which are responsible for presentation of peptides derived from 
TAAs, are cell surface glycoproteins consisting of an invariant β2-microglobulin chain and a 
highly polymorphic heavy chain. They are expressed on the surface of almost all nucleated 
cells and present peptides of eight to twelve amino acids length to T cells.84,85 As mentioned 
above, this peptide:HLA complex is the key structure of the immunological synapse and the 
level at which the immune system recognizes antigenic structures (see Fig 1 and 2). Proteins 
derived from all cellular compartments can be degraded into peptides by the proteasome 
within the cytosol. Afterwards, cytosolic peptides are transported into the lumen of the 
endoplasmic reticulum (ER) via the transporters associated with antigen processing-1 and -2 
(TAP1 and TAP2). Peptide-binding to the HLA class I molecule occurs within the lumen of 
the ER. The peptide-binding complex includes the chaperones calreticulin, ERp57, and 
tapasin. Finally, the peptide:HLA complex is transported to the cell surface through the Golgi 
apparatus.86  
 For surface expression by an HLA molecule, certain amino acids at specific positions 
of the peptide have to bind into so called “anchoring pockets” of the HLA molecule.18,87 
Depending on its polymorphic regions, every HLA allele requires certain amino acid 
combinations for their anchoring pockets.88 If the peptide used for vaccination is not 
compatible with the HLA haplotype of the patient, it will not be presented to the TCR, and an 
immune response against the tumor cannot be primed. Most immunotherapeutic approaches 
in the past have focused on HLA-A*02-restricted peptides since HLA-A*02 is the most 
prevalent HLA-class I allele in Caucasians,89 and therefore it has to be taken into 
consideration, that predominantly HLA-A*02+ patients will benefit from such approaches. By 
analyzing all HLA class I peptides of an individual patient, one can offer a much broader 
range of peptides for vaccination, hence limiting the risk of tumor escape.  
 
Possible sources for tumor-associated antigens are differentiation and 
housekeeping/metabolic antigens, cancer-testis antigens, as well as mutated, differentially 
spliced, overexpressed or viral antigens.90 Although the exclusive expression is not required 
for this approach to work, it certainly reduces the risk of autoimmune reactions. When 
peptide vaccines derived from overexpressed self-antigens are employed, it appears that the 
anti-tumor effect correlates with the rate of autoimmunity.91 For instance, vitiligo is a well-
known phenomenon in the immune response to melanoma and is due to shared 
melanocyte/melanoma antigens – meaning that antigens are presented on both, the healthy 
melanocyte and the dedifferentiated melanoma cell.92,93 In the setting of melanoma 
immunotherapy, the rate of autoimmunity correlates with cancer regression and this side 
effect occurs in a non-essential organ. Thus, vitiligo poses only a relative concern when 
being confronted with a life-threatening disease. However, autoimmune reactions against 
CNS structures are could potentially be far more harmful. A possible solution to this problem 
might be to primarily focus on mutated peptides. By performing whole genome sequencing of 
tumor tissue and normal DNA samples, peptides spanning mutated sequences can be 
defined. As they should only be present on the surface of tumor cells and not on normal 
tissue, the risk for severe autoimmune reactions and collateral damage is reduced. 
Furthermore, the tumor antigen should ideally be expressed on strategically important cell 
subpopulations such as glioma stem cells (GSCs), which play an essential role in tumor 
biology.94,95 GSCs represent only a small fraction of the total tumor burden, but these cells 
are believed to be resistant to chemo- and radiotherapy. Their tumor-initiating capacity is 
linked to glioblastoma recurrence after cytotoxic treatment.96 
 
An important step in understanding T cell activation and adaptive immunity was the 
discovery of techniques to elute peptides directly out of the HLA binding groove, thereby 
being able to investigate the natural HLA ligandome presented on the surface of tumors.97 
Protocols such as the “Tübingen approach” have been applied in the past to identify potential 
tumor antigens.98 This approach differentially analyzes normal versus tumor tissues, 
consequently compares mRNA as well as peptide surface expression and includes 
immunoassays monitoring in vitro T cell responses. However, the expression of a given HLA-
bound peptide on the surface of the cell does not correlate well with the mRNA expression of 
its corresponding source protein.99 In addition, with regards to glioblastoma normal tissue 
samples usually cannot be provided by the neurosurgeon. Thus, a novel approach well 
adapted for the highly individual aspects of glioblastoma tumor biology is needed. Two 
studies analyzed the natural HLA ligandome of glioblastoma using the peptide elution 
technique in combination with mass spectrometry.36,100 A number of possible target antigens 
for peptide vaccination have been described and in vitro T cell studies demonstrated solid 
immune responses. If those ligands will be able to mount an in vivo immune response and 
therefore will be suitable for tumor vaccination is focus of current investigations.   
 
In addition to an HLA class I initiated cytotoxic T cell responses, recent investigations 
have emphasized the role of CD4+ Thelper cells in priming anti-tumor responses after 
vaccination.101 In parallel to other complex immune response, i.e. viral infections,102 CD8+ 
and CD4+ Thelper cell interaction is mandatory for efficient anti-tumor immunity, e.g. by 
escaping activation-induced CTL cell death or supporting the formation of long-term 
memory.103,104 Although the role of CD4+ Thelper cells is being discussed controversially,105 we 
assume that a vaccinating agent should include tumor-associated peptides, which can bind 
to HLA class II molecules and promote a tumor-specific involvement of CD4+ Thelper cells.  
 
In summary, by analyzing the patient-individual HLA ligandome of freshly resected 
glioblastoma specimen in contrast to in vitro or in silico prediction of epitopes, it can be 
ascertained that a selected candidate peptide is actually naturally presented by the tumor in 
vivo. Whole genome sequencing of tumor and normal DNA allows identification of tumor-
specific mutated peptides, thereby reducing the risk of autoimmunity. The aim should be to 
immunize not only with one, but with a cocktail of peptides adapted to the patient`s HLA 
haplotype and to the tumor individual mutations in order to reduce the chance of tumor 
escape. This personalized approach is promising but poses substantial logistical and 
technical challenges. 
 
Suggestions for a peptide-based treatment protocol 
 
Trying to meet all requirements and challenges of the above described antigen 
selection for a successful application of peptide-based immunotherapy against glioblastoma, 
we suggest the following protocol, which is depicted in Figure 3. Directly after initial 
radiological diagnosis and strong suspicion for a malignant primary brain tumor such as 
glioblastoma, the required steps for a patient-specific treatment protocol have to be initiated. 
Together with neurosurgical resection and collection of snap-frozen, as well as vital tumor 
tissue, PBMCs have to be isolated from EDTA-containing blood tubes or ideally, if possible, 
by leukapheresis. In addition to standard neuropathological analysis, GSC cultures are 
initiated and tumor bulk tissue is being snap-frozen for whole tumor HLA ligand elution. 
Afterwards, the patient will receive standard of care treatment by combined radio- and 
chemotherapy.2 During the 6 weeks course of treatment PBMCs are also acquired as healthy 
tissue control for whole genome sequencing of tumor tissue, including detailed HLA-
haplotyping. While GSC cultures are growing a first HLA ligand elution of tumor bulk tissue is 
performed. The concomitant whole genome sequencing will additionally yield valuable 
information about tumor-specific mutations.  One of the most important steps for the patient-
specific targeted vaccine design will then be the antigen selection. First, a comparison of 
eluted HLA ligands and tumor-specific mutations discovered by the whole genome 
sequencing will be performed to detect a sufficient amount of suitable antigens. After 
possible petide modifications to enhance immunogenicity, suitable antigens are synthesized 
and the patients’ T cell response is tested for its reactivity towards the tumor antigens, ideally 
by at least two different standardized assays, e.g. flow cytometry-based dye dilution, 
ELISPOT, thymidine incorporation and/or a CTL assay. If a solid immune CD4+ and CD8+ T 
cell response, ideally against a certain number of HLA class I and –II binding peptides, is 
detected, final GMP synthesis of the multi-peptide vaccination is initiated.  Although there is 
considerable controversy regarding the interaction of temozolomide with immunotherapeutic 
protocols, we propose a minimum of 4 weeks between administration of the individually 
designed peptide-vaccine and the last dose of chemotherapy. Subsequently further PBMC 
samples should be collected and immune response should be monitored to determine T cell 
expansion as well as the optimal time point for re-boosting with the patient-suited multi 
peptide vaccine. The above strategy is in our mind an ideal one, however, as stated before, it 
is logistically very challenging in its implementation and costly. 
 
SUMMARY, OUTLOOK AND FUTURE CHALLENGES 
 
 In this review we discussed challenges for peptide vaccination protocols in 
glioblastoma. One of the most important issues to be overcome is the tumor heterogeneity at 
a molecular and cellular level, which is presumably driven by GSCs along with a naturally 
transforming cell population and maintained by the high prevalence of new mutations within a 
fast growing tumor. This inter- and even intra-individual heterogeneity complicates the 
selection of appropriate targets for vaccination and thereby also the development of “off-the-
shelf” approaches. Therefore, patient-individual treatment protocols are needed. 
Immunosuppressive properties of glioblastoma are mainly the result of cooperating 
processes of selection and mutation, which is summarized under the term immunoediting.41 
Due to the large variety of pathways employed by the tumor to evade, suppress and 
manipulate the immune system, especially in the local tumor environment, peptide 
vaccination strategies have to find appropriate ways to circumvent immunosuppresion to be 
able to translate into clinical success. Since murine studies have produced encouraging 
results of long-term immunity,106 the goal of clinical immunotherapy has to remain achieving 
complete tumor regression. The following strategies represent options to overcome the 
abovementioned hurdles and pave the way to successful immunotherapy in glioblastoma. 
 
 To counteract heterogeneity and circumvent tumor-induced suppression of antigen-
specific T cell responses, tumor vaccines should consist of multiple peptides that ideally 
should elicit efficient CD4+ and CD8+ T cell responses. Targeting multiple tumor-associated 
antigens will enhance the magnitude of immune response and decrease the chance of tumor 
escape by positive clonal selection of antigen-loss variants.90 As described above, given the 
increasing evidence for a central role of GSCs in glioblastoma, a multi-peptide vaccine 
should also target stem cell-associated antigens in order to eliminate potential sources for 
recurrences. One future challenge will be the development of a GSC-targeting 
immunotherapy that avoids an autoimmune response against normal adult neural 
stem/progenitor cells.96 These cells share a similar antigen profile with GSCs and potential 
and mediate an important role after chemo- and radiotherapy-induced tissue destruction. 
They also have been proposed to inhibit glioblastoma growth by inducing cancer cell 
apoptosis.107 Furthermore, to enhance anti-tumor efficacy, vaccines have to include peptides 
eluted from HLA class II for the purpose of eliciting a supportive CD4+ T cell expansion.108 
CD4+ THelper cells orchestrate initiation of an adaptive immune response and augment CTL 
expansion. Murine data has confirmed that CD4+ T cells are essential to generate long-term 
tumor immunity.106,109 Peptide modifications that enhance binding properties to HLA class I 
and -II, without sacrificing tumor-antigen specificity can facilitate immunogenicity and induce 
a greater TCR diversity. In addition, the targeting peptide sequence can be incorporated into 
long peptides to avoid unspecific peptide binding to unoccupied HLA molecules, thereby 
improving natural uptake and processing of the peptide resulting in enhanced presentation 
on antigen presenting cells.110 Modifications like myristilation, amino acid substitution, 
backbone reduction, partial retro-inversion or terminal alterations of the peptide have been 
proposed to further enhance immunogenicity.111 
 
To discuss the challenge of possible targets to clinically counteract tumor 
immunosuppressive in the local tumor environment as well as at the systemic level, two 
principles of adjuvants to peptide vaccination protocols have to be considered – relieving 
immunosuppression and boosting the induced anti-tumor response. Regarding antagonizing 
immunosuppression, most approaches aim to deplete regulatory T cells prior to 
immunization. Clinical trials in humans primarily used agents like anti-CD25 antibodies112 or 
low-dose cyclophosphamide to achieve a depletion of CD4+ CD25+ regulatory T cells.29 A 
multitude of approaches to selectively target regulatory T cells are under investigation,113 e.g. 
toxin-fused IL-2 to target the CD25 epitope.114 With removal of one of the central mediators 
within the local tumor environment, less soluble factors like IL-10 and TGF- are secreted 
and more IL-2 is available for expansion of tumor-specific CTLs. Unfortunately, since T cells 
also upregulate the high-affinity IL-2 receptor alpha-chain (CD25) upon activation, 
administration of an anti-CD25-specific antibody depletes antigen-activated T cells, 
presumably weakening the intrinsic anti-tumor response of the host. Therefore, additional 
studies are needed that will yield valuable results about timing and improvement of selectivity 
of lymphodepletion. Another strategy is to complement peripheral delivery of DCs with 
intratumoral (IT) injections of peptide-pulsed DCs (pDC). Mice treated with IT-pDC plus 
subcutaneous (SC) pDC survived longer than mice treated by SC-pDC only. Further, the 
intratumoral injection of pDCs resulted in a significant decrease in FoxP3+ regulatory T cells, 
and an increase in CD8+ T cells, indicating a change in the local tumor environment favoring 
anti-tumor responses.115 Besides the use of antibodies to deplete Tregs and the local 
administration of cells facilitating immune activation, new compound release systems, 
directly applied to the tumor bed after surgical resection, could be able to deliver antibodies 
or cytokines to defuse the local immunosuppressive milieu of the tumor. Inspired by the 
gliadel™ principle, where biodegradable polymer wafers are implanted after tumor removal 
to continuously release the chemotherapeutic agents carmustine,116 neurosurgical 
interventions could include placement of immunomodulatory agents directly to the tumor bed.  
 
Besides directly focusing on the presence of regulatory T cells, the inhibition of 
soluble factors, especially TGF- might facilitate improvement to an effective immune 
response. In that regard, a randomized study exploring the local delivery of TGF-β antisense 
oligonucleotides via catheter system confirmed the feasibility of this approach, but did not 
examine target inhibition and did not confirm its efficacy.117 Current approaches to inhibit 
TGF-β pathway activation focus on small molecule inhibitors of Alk5, the major TGF-β 
receptor I, e.g., using LY2157299.118 
 
To support the priming and execution of the peripherally activated anti-tumor 
response new compound release systems like microparticles containing cytokines like IL-
7,119, IL-15, IL-21, IFN-, antibodies intercepting IL-10 or small molecules enhancing APC 
function, T cell activation and proliferation, breaking down the barriers for an efficient tumor 
cell lysis by glioma-specific T cells are under investigation. Additionally boosting the clonal 
expansion can be achieved by TLR agonists like poly I:C or imiquimod.120  
 
 The modality of peptide vaccines offers many additional therapeutic options besides 
targeting the tumor cells directly. Immunization with antigens exclusively expressed during 
angiogenesis could, for example, limit the supply of nutrition to the expanding tumor.121,122 
Further, radio- and chemotherapy applies selective pressure on the tumor. This has been 
shown to result in mutations conferring properties of radio- and chemotherapy resistance to 
the tumor. The proteins mediating mechanisms of resistance now may result in new target 
antigens for immunotherapy, in the sense that peptide vaccines could not only constitute as 
an independent treatment approach,123 but also serve as a synergistic tool supporting other 
treatment modalities. Individualized peptide-vaccination is therefore not only able to target 
patient-specific mutations and cell subpopulations, but also has the potential to be combined 
with other treatment modalities such as radio- and chemotherapy and represents an optimal 
complementation to neurosurgical treatment. Since immunotherapy is unlikely to be able to 
eradicate a large established tumor burden by itself, it is depending, at least for now, on 
neurosurgical resection for both tissue sampling and reduction of tumor load. 
  
CONCLUSION 
 
 The heterogeneity and the transforming nature of glioblastoma as well as tumor-
associated immunosuppression and immune evasion mechanisms pose a major challenge to 
treating physicians. Since conventional treatment options such as surgery, radio- and 
chemotherapy failed to profoundly improve overall survival; new treatment modalities are 
desperately needed. Immunotherapy offers high specificity and appears to be one of the 
most promising targeted approaches. We suggest a protocol to define tumor-associated 
antigens for peptide-based immunotherapy. Key elements of our approach are patient-
individual screening for antigens, the use of multiple peptides covering all HLA alleles of the 
patient, the inclusion of both HLA class I and -II peptides, the focus on tumor-specific 
mutated peptides, and the definition of HLA ligands eluted from GSCs. Suitable antigenic 
peptides can then be used for peptide vaccination, but also for the loading of dendritic cells 
or for priming CTLs prior to an adoptive transfer to the patient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE LEGENDS 
 
Figure 1: Key players in immunotherapy 
The schematic overview depicts the idealized vaccination-induced peripheral priming of a 
tumor-specific immune response. After peptide uptake and processing peripheral antigen 
presenting cells, especially dendritic cells, present the antigen via HLA-class I and -II 
molecules to tumor-specific T cells. After TCR-peptide:HLA and costimulatory molecule-
induced activation, T cells proliferate and execute their effector functions. CD4+ Thelper cells 
promote the perpetuation of the mounted immune response by activating local antigen 
presenting cells (APC), while CD8+ cytotoxic T cells directly lyse tumor cells through 
induction of apoptosis by, i.e. perforin, granzyme and granulysin. Glioblastoma cells try to 
evade immune-mediated lysis by attracting regulatory T cells, thereby promoting an anti-
inflammatory milieu and manipulating the local tumor environment in their  
 
Figure 2: HLA presentation of mutated peptides and CD8+ T cell interaction 
Cellular proteins of glioblastoma cells – some of them carrying tumor-specific mutated 
sequences (shown in red) – are degraded into peptides by the proteasome within the cytosol. 
These peptides are transported into the lumen of the endoplasmic reticulum via the 
transporter associated with antigen processing (TAP) and loaded onto HLA class I 
molecules. The peptide:HLA complex is transported to the cell surface via the Golgi 
apparatus and presents potential tumor antigens to CD8+ cytotoxic T cells, which recognize 
the antigen via their cognate T cell receptor (TCR) . 
 
Figure 3: Personalized peptide-based treatment protocol 
A suggestion for a individualized peptide-based glioblastoma vaccination algorhythm. 
PBMCs = peripheral blood mononuclear cells; GSCs = glioma stem cells; HLA = human 
leukocyte antigen; GMP = good manufacturing practice 
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Table 1: Ongoing clinical trials involving peptide vaccines targeting glioblastoma according to the database of ClinicalTrials.gov 
Phase Estimated 
Completion / Size 
Sponsor  Protocol  
Phase I/II  
ID: NCT00293423 
Date: 12/2013 
Enrollment: 50 
University of California, San 
Francisco 
Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) vaccine for patients with recurrent high-grade 
glioma.  
Phase I 
ID: NCT01403285 
Date: 03/2014 
Enrollment: 25 
immatics Biotechnologies 
GmbH 
Trial of peptide-based glioma vaccine IMA950 in patients with glioblastoma.  
IMA950:  multi-peptide vaccine containing 11 tumor-associated peptides (TUMAPs) found in a majority of 
glioblastomas.  
Phase I  
ID: NCT01250470 
Date: 09/2014 
Enrollment: 9 
Roswell Park Cancer 
Institute 
Study of safety, tolerability and immunological effects of SVN53-67/M57-KLH in patients with Survivin-positive 
malignant gliomas.  
Phase I  
ID: NCT00626015 
Date: 11/2013 
Enrollment: 20 
John Sampson, Duke 
University Medical Center 
Chemotherapy, Radiation Therapy, and Vaccine (PEP-3-KLH ) Therapy With Basiliximab in Treating Patients 
With Glioblastoma Multiforme That Has Been Removed by Surgery  
Phase I/II  
ID: NCT01920191 
Date: 08/2014 
Enrollment: 16 
University Hospital, Geneva Study of intradermal IMA950 peptide-based vaccine adjuvanted with intramuscular Poly-ICLC in combination 
with temozolomide in newly diagnosed HLA-A2 glioblastoma patients.  
Phase II  
ID: NCT01814813 
Date: 04/2016 
Enrollment: 222 
Alliance for Clinical Trials in 
Oncology 
Randomized trial comparing the efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) vaccine 
given with Bevacizumab versus Bevacizumab alone in the treatment of surgically resectable recurrent 
glioblastoma.  
 
Experimental: Arm 1, HSPPC-96, concomitant Bevacizumab. 
Experimental: Arm 2, HSPPC-96 with Bevacizumab at progression 
Active Comparator: Arm 3, Bevacizumab 
Phase II 
ID: NCT00905060 
Date: 01/2014 
Enrollment: 555 
University of California, San 
Francisco 
Multi-center, single arm investigation of HSPPC-96 vaccine with Temozolomide in patients with newly 
diagnosed glioblastoma. 
Phase II  
ID: NCT00643097 
Date: 06/2016 
Enrollment: 48 
 
John Sampson, Duke 
University Medical Center 
A Complementary trial of an immunotherapy vaccine against tumor-specific EGFRvIII. 
 
Arm I: Patients receive PEP-3-KLH conjugate vaccine and Sargramostim (GM-CSF) intradermally on days 1, 
15, and 29 and then monthly in the absence of disease progression or unacceptable toxicity. 
Arm II: Patients receive placebo vaccine intradermally on days 1, 15, and 29. Patients then receive PEP-3-KLH 
conjugate vaccine and GM-CSF monthly in the absence of disease progression or unacceptable toxicity. 
Phase II 
ID: NCT01498328 
  
Date: 06/2015 
Enrollment: 168 
Celldex Therapeutics A Phase II Study of Rindopepimut/GM-CSF in patients with relapsed EGFRvIII-positive glioblastoma (ReACT). 
 
Experimental: Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut. 
Experimental: Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control 
Experimental: Group 2 and 2C: Refractory to Bevacizumab 
Phase III 
ID: NCT01498328 
Date: 11/2016 
Enrollment: 440 
Celldex Therapeutics An international, randomized, double-blind, controlled study of Rindopepimut/GM-CSF with adjuvant 
Temozolomide in patients with newly diagnosed, surgically resected, EGFRvIII-positive glioblastoma (ACT IV). 
 
Experimental: Rindopepimut /GM-CSF plus Temozolomide 
Active Comparator: KLH plus Temozolomide 
Each: Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or 
intolerance. 
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